VERA - CIK 0001831828
The table below shows Vera Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $215.26M | $126.17M | $78.22M | $68.99M | $22.48M | $45.21M |
| SG&A | $100.22M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $41.00M |
| $23.79M |
| $21.91M |
| $11.92M |
| $4.04M |
| Operating income | -$315.47M | -$167.17M | -$102.01M | -$90.90M | -$34.40M | -$52.24M |
| Income tax | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | -$1.00K |
| Net income | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | -$53.41M |
| EPS (diluted) | -$4.66 | -$2.75 | -$2.25 | -$3.35 | -$2.43 | - |